Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

gene-editing

- PMLiVE

Study reveals molecular signatures driving immune cell attacks in chronic neurological diseases

MS is a chronic neurological disease that affects more than two million people worldwide

regeneron headquarters

Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol

Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment

- PMLiVE

New genetic risk tool could predict multiple sclerosis in young adults much earlier

Approximately 2.8 million people worldwide are affected by the disabling neurological disease

- PMLiVE

Sanofi’s investigational frexalimab shows promise in relapsing forms of MS

Results from a mid-stage of the candidate were recently published in the NEJM

regeneron headquarters

Regeneron to acquire 2seventy’s investigational cell therapy pipeline

An estimated 150 2seventy employees will join Regeneron’s new research and development unit

- PMLiVE

Survey of US oncologists highlights advanced lung cancer research gaps  

Non-small cell lung cancer is responsible for approximately 85% of all lung cancers

- PMLiVE

UK government announces nearly £50m to expand dementia research sites

The funding will be used to enable more people to take part in clinical trials for dementia

- PMLiVE

Michael J Fox Foundation awards Vesper Bio over $870,000 for Parkinson’s treatment

Vesper is currently developing VES001 for GRN-mutated frontotemporal dementia

- PMLiVE

New framework establishes two tests for use in clinical trials for Parkinson’s

The neurological condition currently affects around 145,000 people in the UK

- PMLiVE

Study shows blood test could be as accurate as lumbar punctures for detecting Alzheimer’s

ALZpath successfully detected levels of a form of the hallmark tau protein in the blood

- PMLiVE

Novartis and Voyager enter gene therapy partnership worth over $1.2bn

The companies will advance candidates for Huntington’s disease and spinal muscular atrophy

- PMLiVE

Roche and Monte Rosa enter molecular glue degrader partnership worth over $2bn

The companies will work on therapies for targets in cancer and neurological diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links